PRQR logo

PRQRProQR Therapeutics N.V

$1.41
$0.06
(4.08%)
Today
Closed $1.41
$0.02
(1.42%)
After Hours
Updated: 07:45 PM EDT
Reported EarningsMay 12
Mkt Cap$154.88M
Vol466,198.00
News
all
press releases
Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -40.02% and -2.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
More News
News Placeholder
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of +17.95% and -7.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Down 24.4% in April
ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) was the target of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling 1,261,281 shares, a decrease of 24.4% from the March 31st total of 1,667,465 shares. Currently, 1.3% of the shares...
MarketBeat
News Placeholder
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Analysts
ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have...
MarketBeat
News Placeholder
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50 Day Moving Average - Should You Sell?
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above Fifty Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday...
MarketBeat
News Placeholder
Aberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQR
Aberdeen Group plc increased its holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) by 28.4% during the fourth quarter, according to its most recent 13F filing with the Securities and...
MarketBeat
News Placeholder
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter
ProQR Therapeutics (NASDAQ:PRQR) outlined multiple pipeline updates and development priorities during its virtual investor and analyst event, highlighting upcoming clinical readouts for its lead RNA...
MarketBeat
News Placeholder
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages
ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight analysts that are covering the stock, MarketBeat reports. One analyst...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.